Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the big pharma will need to work on differentiating the drug from other CDK 4/6 therapies.

Two wild goats play-fight on the edge of a rock cliff with horns interlocked.
Lilly's abemaciclib will face off with Pfizer's Ibrance if approved in 2018

It is unclear how much commercial traction Eli Lilly & Co. will get with incoming breast cancer therapy abemaciclib, analysts from Bernstein said after the big pharma presented Phase III data from the MONARCH-3 trial at the European Society for Medical Oncology's annual meeting in Madrid.

"The presentation of full MONARCH-3 results will largely support investors' disbelief that abemaciclib will be clearly superior [to market leading...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.